Galenea has demonstrated commitment to building relationships and forming alliances with pharmaceutical and biotechnology companies, foundations, and academic institutions, with the goal of taking innovative products to the clinic.
Galenea has entered a strategic neuroscience collaboration with Eisai Co. Ltd., to develop synaptic modulators for neurodegenerative diseases by applying our synaptic transmission platform. The collaboration's goals are the discovery and development of novel therapeutics for neurodegeneration mediated by a disease-specific protein.
Galenea has forged a multi-year collaboration with the CHDI foundation focused on synaptic dysfunction in Huntington's disease (HD). Under this collaboration, Galenea is employing its synaptic transmission platform to define and address synaptic and network alterations in HD. The collaboration's goals are the discovery and development of novel therapeutics that restore synaptic and network activity in HD.
Galenea has partnered with the Stanley Medical Research Institute (SMRI) to advance our pro-cognitive, antipsychotic therapeutic program into the clinic. Under the partnership, SMRI is providing funding to Galenea, which includes support for a proteomics collaboration with The Broad Institute to identify the molecular target of a novel series of pro-cognitive compounds that were identified using our synaptic transmission platform. The goals of the partnership are the discovery and development of a new class of therapies that address the cognitive deficits in schizophrenia.
For more information, please contact: CorpDev@galenea.com